Want to see FR:ALTME full AI Analyst Report?
TME Pharma N.V. (ALTME) AI Stock Analysis
Top Page
TME Pharma N.V.
(Paris:ALTME)
The score is held down primarily by weak financial performance (pre-commercial revenue profile, ongoing losses, negative free cash flow, and negative equity with rising debt), which implies elevated financing risk. This is only partially offset by moderately positive technical momentum (price above key moving averages and positive MACD). Valuation remains challenging to assess favorably due to negative earnings (negative P/E) and no dividend yield.
TME Pharma N.V. (ALTME) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 11.77M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.92M
- Price to Earnings (P/E)
- -3.6
- Beta (1Y)
- -0.69
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- France
- Employees
- 12
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
TME Pharma N.V. Business Overview & Revenue Model
Company Description
TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipelin...
How the Company Makes Money
Public, company-specific detail sufficient to describe TME Pharma N.V.’s revenue model and key revenue streams in a factual way is not available in the provided prompt context; therefore: null
TME Pharma N.V. Financial Statement Overview
Summary
Financial fundamentals are weak: the company is pre-commercial with near-zero revenue, persistent large operating losses, and consistently negative operating/free cash flow. Balance sheet risk is elevated with negative shareholders’ equity in the latest period and sharply higher debt in 2025, implying continued reliance on external financing.
Income Statement
12Very NegativeBalance Sheet
22NegativeCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 19.00K | 17.00K | 0 | 33.00K |
| Gross Profit | -8,000 | -8,000 | -78.00K | -127.00K | -92.00K | -65.97K |
| EBITDA | -2.90M | -2.90M | -5.17M | -5.07M | -11.63M | -12.88M |
| Net Income | -3.29M | -3.29M | -5.72M | -6.74M | -15.13M | -14.45M |
Balance Sheet | ||||||
| Total Assets | 2.14M | 2.14M | 3.41M | 2.49M | 5.24M | 9.77M |
| Cash, Cash Equivalents and Short-Term Investments | 2.02M | 2.02M | 3.25M | 2.25M | 4.63M | 9.48M |
| Total Debt | 2.39M | 2.39M | 56.00K | 1.17M | 4.09M | 2.44M |
| Total Liabilities | 3.72M | 3.72M | 1.79M | 2.79M | 6.51M | 5.27M |
| Stockholders Equity | -1.58M | -1.58M | 1.61M | -294.00K | -1.27M | 4.51M |
Cash Flow | ||||||
| Free Cash Flow | -3.42M | -3.42M | -4.65M | -5.65M | -12.16M | -12.39M |
| Operating Cash Flow | -3.42M | -3.42M | -4.63M | -5.63M | -12.14M | -12.38M |
| Investing Cash Flow | 8,000 | 8,000 | -21.00K | -19.00K | -21.00K | -14.00K |
| Financing Cash Flow | 2.18M | 2.18M | 5.66M | 3.27M | 7.29M | 11.50M |
TME Pharma N.V. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTME, the sentiment is Positive. The current price of 0.12 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.12, and above the 200-day MA of 0.08, indicating a bullish trend. The MACD of 0.00 indicates Negative momentum. The RSI at 54.87 is Neutral, neither overbought nor oversold. The STOCH value of 48.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALTME.
TME Pharma N.V. Peers Comparison
Overall Rating
- FR:ALTME48Neutral
FR:IPH47Neutral
FR:NANO46Neutral
FR:TNG46Neutral
FR:OSE43Neutral
FR:ALCLS42.5Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FR:ALTME | 48Neutral | EUR 11.77M | -3.55 | 305.72% | ― | ― | ― |
| FR:IPH | 47Neutral | EUR 140.30M | -2.46 | 152.56% | ― | -29.48% | 7.91% |
| FR:NANO | 46Neutral | EUR 1.43B | -25.56 | 89.71% | ― | ― | ― |
| FR:TNG | 46Neutral | EUR 202.03M | -4.34 | -29.36% | ― | 189.81% | 38.50% |
| FR:OSE | 43Neutral | EUR 45.93M | -1.16 | -96.73% | ― | -96.25% | -197.89% |
| FR:ALCLS | 43Neutral | EUR 75.07M | -1.78 | -94.14% | ― | -5.98% | -8.67% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALTME | TME Pharma N.V. | 0.12 | 0.03 | 36.26% | |
| FR:IPH | Innate Pharma S.A. | 1.26 | -0.39 | -23.51% | |
| FR:NANO | Nanobiotix SA | 28.12 | 12.36 | 78.43% | |
| FR:TNG | Transgene SA | 0.73 | -0.63 | -46.62% | |
| FR:OSE | OSE Immunotherapeutics | 1.95 | -3.75 | -65.75% | |
| FR:ALCLS | Cellectis SA | 1.04 | -1.90 | -64.63% |
TME Pharma N.V. Corporate Events
TME Pharma Secures Exclusive Talks With Japan’s TMS to Advance NOX-A12 Glioblastoma Program
TME Pharma has entered into an exclusive six-month negotiation agreement with Japanese clinical-stage biotech TMS Co., which will form a dedicated subsidiary to finance and advance global development of NOX-A12 for glioblastoma. The non-binding frame...
TME Pharma Extends Debt Maturity and Secures New Bond Financing to 2028
TME Pharma has extended the maturity of all its outstanding debt from May 2027 to 30 June 2028 and secured two new bond financings, improving financial visibility until the second quarter of 2028. The company is favoring bond over equity funding to c...
TME Pharma CEO Emphasizes Cash Discipline and Strategic Partnering for Lead Cancer Asset
TME Pharma, a clinical-stage biotech group developing therapies for brain cancer and eye diseases, is centered on two key RNA aptamer assets targeting the tumor microenvironment and fibrotic pathways. The firm is advancing its NOX-A12 program in glio...
TME Pharma moves to license glioblastoma drug NOX-A12 and widens strategic focus
TME Pharma is advancing late-stage partnering plans for its flagship oncology drug NOX-A12, entering a final evaluation phase with two potential partners for a licensing deal to fund and run a phase 2 trial in glioblastoma. The asset benefits from or...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026